drugset / Trial / NCT06769555
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Withdrawn
Institute of Hematology & Blood Diseases Hospital, China
Keymed Biosciences Co.Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the effectiveness and safety of CM-336, which is a BCMA/CD3 BiTE, in patients with relapsed/refractory AL amyloidosis or newly diagnosed AL amyloidosis with insufficient depth of hematologic response after induction therapy.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2026-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | 80 mg | Subcutaneous |